These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 25576921)

  • 21. Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents.
    McCormick A; Earp E; Leeson C; Dixon M; O'Donnell R; Kaufmann A; Edmondson RJ
    Int J Gynecol Cancer; 2016 May; 26(4):632-9. PubMed ID: 26905328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
    Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H
    Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
    Minami D; Takigawa N; Takeda H; Takata M; Ochi N; Ichihara E; Hisamoto A; Hotta K; Tanimoto M; Kiura K
    Mol Cancer Res; 2013 Feb; 11(2):140-8. PubMed ID: 23239809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
    Wang J; Ding Q; Fujimori H; Motegi A; Miki Y; Masutani M
    Oncotarget; 2016 Feb; 7(7):7701-14. PubMed ID: 26713604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.
    Pai Bellare G; Saha B; Patro BS
    Br J Cancer; 2021 Mar; 124(7):1260-1274. PubMed ID: 33473172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PJ-34 inhibits PARP-1 expression and ERK phosphorylation in glioma-conditioned brain microvascular endothelial cells.
    Motta C; D'Angeli F; Scalia M; Satriano C; Barbagallo D; Naletova I; Anfuso CD; Lupo G; Spina-Purrello V
    Eur J Pharmacol; 2015 Aug; 761():55-64. PubMed ID: 25934569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
    Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RAD51-Mediated DNA Homologous Recombination Is Independent of
    Sinha A; Saleh A; Endersby R; Yuan SH; Chokshi CR; Brown KR; Kuzio B; Kauppinen T; Singh SK; Baker SJ; McKinnon PJ; Katyal S
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
    Rasmussen RD; Gajjar MK; Jensen KE; Hamerlik P
    Mol Oncol; 2016 May; 10(5):751-63. PubMed ID: 26794465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BubR1 is involved in regulation of DNA damage responses.
    Fang Y; Liu T; Wang X; Yang YM; Deng H; Kunicki J; Traganos F; Darzynkiewicz Z; Lu L; Dai W
    Oncogene; 2006 Jun; 25(25):3598-605. PubMed ID: 16449973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
    Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
    Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
    Yang ZM; Liao XM; Chen Y; Shen YY; Yang XY; Su Y; Sun YM; Gao YL; Ding J; Zhang A; He JX; Miao ZH
    Acta Pharmacol Sin; 2017 Jul; 38(7):1038-1047. PubMed ID: 28414200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein tyrosine phosphatase receptor U (PTPRU) is required for glioma growth and motility.
    Zhu Z; Liu Y; Li K; Liu J; Wang H; Sun B; Xiong Z; Jiang H; Zheng J; Hu Z
    Carcinogenesis; 2014 Aug; 35(8):1901-10. PubMed ID: 24876153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miR-656 inhibits glioma tumorigenesis through repression of BMPR1A.
    Guo M; Jiang Z; Zhang X; Lu D; Ha AD; Sun J; Du W; Wu Z; Hu L; Khadarian K; Shen J; Lin Z
    Carcinogenesis; 2014 Aug; 35(8):1698-706. PubMed ID: 24480809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TCH1036, a indeno[1,2-c]quinoline derivative, potentially inhibited the growth of human brain malignant glioma (GBM) 8401 cells via suppression of the expression of Suv39h1 and PARP.
    Liao HF; Lee CC; Hsiao PC; Chen YF; Tseng CH; Tzeng CC; Chen YL; Chen JC; Chang YS; Chang JG
    Biomed Pharmacother; 2016 Aug; 82():649-59. PubMed ID: 27470408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.
    Zheng H; Ying H; Yan H; Kimmelman AC; Hiller DJ; Chen AJ; Perry SR; Tonon G; Chu GC; Ding Z; Stommel JM; Dunn KL; Wiedemeyer R; You MJ; Brennan C; Wang YA; Ligon KL; Wong WH; Chin L; DePinho RA
    Nature; 2008 Oct; 455(7216):1129-33. PubMed ID: 18948956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis.
    Martin-Oliva D; Aguilar-Quesada R; O'valle F; Muñoz-Gámez JA; Martínez-Romero R; García Del Moral R; Ruiz de Almodóvar JM; Villuendas R; Piris MA; Oliver FJ
    Cancer Res; 2006 Jun; 66(11):5744-56. PubMed ID: 16740713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair.
    Bryant HE; Helleday T
    Nucleic Acids Res; 2006; 34(6):1685-91. PubMed ID: 16556909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.